Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507862 | 1.00 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL15027986 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL5512711 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL1357221 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL187285 | 0.89 | LMNA (0.68) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL23091 | 0.88 | — | — | |
| SCHEMBL8672325 | 0.85 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL29662067 | 0.85 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL20928 | 0.85 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 | |
| SCHEMBL538230 | 0.85 | LMNA (0.93) | LMNABLMPTPN1MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157442-B2 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1209166-B1 | NOVEL A-500359 DERIVATIVES | SANKYO CO (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030171330-A1 | Antibacterial compound | SANKYO COMPANY, LIMITED (JP) | 2003-09-11 | — | — | US | disclosed |
| EP-1209166-A1 | NOVEL A-500359 DERIVATIVES | Sankyo Company, Limited (JP) | 2002-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171330-A1 | Antibacterial compound | TLR1, MPO, O60361 | LMNA 4477/4885BLM 2245/4885PTPN1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.